Citations

Clear

117 citation(s) found for "Carson, C C".

SARS‐CoV‐2‐related and Covid‐19 vaccine‐induced thromboembolic events: A comparative review
Afshar, Zeinab Mohseni , Barary, Mohammad , Hosseinzadeh, Rezvan , Alijanpour, Amirmasoud , Miri, Seyed Rouhollah , Carson‐Chahhoud, Kristin , Länger, Florian, Ebrahimpour, Soheil , Barary, Mohammad , Carson-Chahhoud, Kristin , Alijanpour, Amirmasoud , Babazadeh, Arefeh , Sio, Terence T. , Sullman, Mark J. M.

Mayo Clinic

Reviews in Medical Virology | February 3, 2022 | Volume: 32 | Issue: 4 | Pages: No page available

10.1002/rmv.2327 | PMID 35112763 Get It

AbstractSince the start of the pandemic, thrombotic events have been a well‐known and severe complication associated with severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) infection. Nevertheless, the initiation of vaccination programs brought another rare yet highly fatal thrombotic event, vaccine‐induced immune thrombotic thrombocytopaenia, which has caused extensive debate regarding the safety of vaccines. This review defines the thromboembolic events following infection and vaccination, identifies their risk factors, describes their pathophysiology, and discusses their management, treatment, and prevention.
Challenges posed by COVID‐19 in cancer patients: A narrative review
Afshar, Zeinab Mohseni , Hosseinzadeh, Rezvan , Barary, Mohammad , Ebrahimpour, Soheil , Alijanpour, Amirmasoud , Hosseinzadeh, Dariush , Miri, Seyed Rouhollah , Sio, Terence T. , Sullman, Mark J. M. , Carson‐Chahhoud, Kristin , Mohseni Afshar, Zeinab , Sayad, Babak , Miri, Seyed Rouhollah , Sio, Terence T , Sullman, Mark J M , Carson-Chahhoud, Kristin , Babazadeh, Arefeh , Barary, Mohammad , Alijanpour, Amirmasoud , Miri, Seyed Rouhollah

Mayo Clinic

Cancer Medicine | December 24, 2021 | Volume: 11 | Issue: 4 | Pages: 1119-1135

10.1002/cam4.4519 | PMID 34951152 Get It

AbstractA novel coronavirus, or severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2), was identified as the causative agent of coronavirus disease 2019 (COVID‐19). In early 2020, the World Health Organization declared COVID‐19 the sixth public health emergency of international concern. The COVID‐19 pandemic has substantially affected many groups within the general population, but particularly those with extant clinical conditions, such as having or being treated for cancer. Cancer patients are at a higher risk of developing severe COVID‐19 since the malignancy and chemotherapy may negatively affect the immune system, and their immunocompromised condition also increases the risk of infection. Substantial international efforts are currently underway to develop specific methods for diagnosing and treating COVID‐19. However, cancer patients’ risk profiles, management, and outcomes are not well understood. Thus, the main objective of this review is to discuss the relevant evidence to understand the prognosis of COVID‐19 infections in cancer patients more clearly, as well as helping to improve the clinical management of these patients.
Family Conflict and Older Chinese Americans’ Self-Efficacy in End-of-Life Care Planning: The Role of Acculturation
Wang, Kaipeng , Liu, Yanqin , Fries, Carson De, Sun, Fei , Fries, Carson M. De

Mayo Clinic

Innovation in Aging | December 17, 2021 | Volume: 5 | Issue: Supplement_1 | Pages: 569-570

10.1093/geroni/igab046.2188 Get It

Abstract Family involvement in end-of-life (EOL) care is critical to ensure older adults’ health and quality of life. Older adults’ self-efficacy in discussing EOL care plans with family members can facilitate family involvement in EOL care planning. Research shows that family relationships are associated with self-efficacy in discussing EOL care with family members among older Chinese Americans. However, the roles of family conflict and acculturation remain unknown. This study examines the association between family conflict and self-efficacy in discussing EOL care with family members and whether such an association differs by acculturation levels among older Chinese Americans. Data were collected from 207 Chinese Americans aged 65-102 in two metropolitan areas in 2017. Ordinary least squares regression was conducted to examine the association between family conflict, acculturation, and self-efficacy in discussing EOL care with family. Family conflict was negatively associated with older adults’ self-efficacy in discussing EOL care with family. More specifically, the negative association between family conflict and self-efficacy in discussing EOL care with family members was more pronounced for those with higher levels of acculturation. Findings highlighted differential effects of family conflict on self-efficacy of EOL care plan discussion for older adults with different acculturation levels. Those with higher acculturation may be more independent in their EOL care planning and aware of the possible negative effects of family conflict in their EOL care planning discussions. Acculturation needs to be considered by geriatric health providers to develop family-centered interventions in improving end-of-life care planning for this population.
Autoimmune conditions in the World Trade Center general responder cohort: A nested case‐control and standardized incidence ratio analysis
Sacks, Henry S. , Smirnoff, Margaret, Carson, Deborah A. , Cooney, Michael L. , Shapiro, Moshe , Hahn, Christopher J., Dasaro, Christopher R. , Crowson, Cynthia S. , Tassiulas, Ioannis, Hirten, Robert , Cohen, Benjamin L., Haber, Richard S., Crane, Michael A. , Harrison, Denise , Moline, Jacqueline , Udasin, Iris , Todd, Andrew C. , Teitelbaum, Susan L. , Crowson, Cynthia, Sloan, Nancy L , Davies, Terry F. , Simpson, David Martin , Luft, Benjamin J.

Mayo Clinic

American Journal of Industrial Medicine | November 26, 2021 | Volume: 65 | Issue: 2 | Pages: 117-131

10.1002/ajim.23313 | PMID 34825393 Get It

AbstractBackgroundThe World Trade Center (WTC) general responder cohort (GRC) was exposed to environmental toxins possibly associated with increased risk of developing autoimmune conditions.ObjectivesTwo study designs were used to assess incidence and risks of autoimmune conditions in the GRC.MethodsThree clinically trained professionals established the status of possible GRC cases of autoimmune disorders adhering to diagnostic criteria, supplemented, as needed, by specialists’ review of consenting responders’ medical records. Nested case‐control analyses using conditional logistic regression estimated the risk associated with high WTC exposure (being in the 9/11/2001 dust cloud or ≥median days' response worked) compared with low WTC exposure (all other GRC members'). Four controls were matched to each case on age at case diagnosis (±2 years), sex, race/ethnicity, and year of program enrollment. Sex‐specific and sensitivity analyses were performed. GRC age‐ and sex‐adjusted standardized incidence ratios (SIRs) were compared with the Rochester Epidemiology Project (REP). Complete REP inpatient and outpatient medical records were reviewed by specialists. Conditions meeting standardized criteria on ≥2 visits were classified as REP confirmed cases.ResultsSix hundred and twenty‐eight responders were diagnosed with autoimmune conditions between 2002 and 2017. In the nested case‐control analyses, high WTC exposure was not associated with autoimmune domains and conditions (rheumatologic domain odds ratio [OR] = 1.03, 95% confidence interval [CI] = 0.77, 1.37; rheumatoid arthritis OR = 1.12, 95% CI = 0.70, 1.77). GRC members had lower SIR than REP. Women's risks were generally greater than men's.ConclusionsThe study found no statistically significant increased risk of autoimmune conditions with WTC exposures.
TMOD-18. DIRECT IN VIVO CRISPR SCREEN IDENTIFIES COOPERATING TUMOR SUPPRESSORS THAT DRIVE PROGRESSION OF IDH1-MUTANT LOW-GRADE GLIOMA TO AGGRESSIVE GLIOBLASTOMA
Yanchus, Connor , Tsai, Ricky , Jiang, Lingyan , Ali, Asma, Carson, Brittany B. , Pawling, Judy , Fortin, Jérôme, Zhou, Lily , Elia, Andrew , Dennis, James W. , Mak, Tak W. , Zadeh, Gelareh , Jenkins, Robert B. , Drucker, Kristen , Kollmeyer, Thomas M. , Malik, Ahmad , Al‐Zahrani, Khalid N. , Loganathan, Sampath K. , Taylor, Michael D. , Dirks, Peter , Schramek, Daniel

Mayo Clinic

Neuro-Oncology | November 18, 2021 | Volume: 23 | Issue: Supplement_6 | Pages: vi219-vi219

10.1093/neuonc/noab196.879 Get It

Abstract Low-grade glioma (LGG) are generally slowly growing brain cancers, that frequently undergo malignant progression to aggressive, secondary glioblastoma with a dismal prognosis. By combining genetically engineered Idh1-mutant mice with in vivo CRISPR gene editing we generated a mouse model faithfully recapitulating the founder mutations of LGG. Clonal activation of the neomorphic Idh1 R132H mutation cooperates with Trp53 and Atrx mutations to trigger development of brain tumors but only with ~30% penetrance and very long latency. To elucidate the molecular mechanisms underlying the malignant progression of IDH1-mutant LGG, we devised and deployed a direct in vivo CRISPR screen targeting genes commonly mutated in human IDH-mutant secondary glioblastoma. Stereotaxic delivery of a lentiviral sgRNA library targeting the mouse orthologs of these genes into the brain of Idh1 R132H ;Trp53;Atrx;Cas9 and control Idh1 wt ;Trp53;Atrx;Cas9 compound mutant mice resulted in rapid formation of tumors that recapitulate human Idh1-mutant glioblastoma. Deconvoluting the screen showed that PI3K pathway members Pten and Pik3ca as well as Notch1, Smarca4 and Fat1 are preferentially enriched in Idh1 R132H-tumors, while Rb1 and NF2 were enriched in Idh1 wt tumors. Co-mutation analysis further identified additional co-occurring driver combinations such as Bcor-Met, Olig2-Met, Olig2-Med12 or Bcor-Olig2. We validated the tumor suppressive function of Notch1 and Pten using conventional floxed knock-out alleles and found that Notch1 functions in a haploinsufficient manner. Interestingly, Idh1 R132H did not alter tumor latency or pathology in a high grade p53;Pten;Rb1 mutant background, indicating that the neomorphic IDH-mutations can drive low but not high grade glioma development. Our study provides a functional landscape of gliomagenesis suppressors in vivo.
Coronavirus disease 2019 (Covid‐19) vaccination recommendations in special populations and patients with existing comorbidities
Afshar, Zeinab Mohseni , Janbakhsh, Alireza , Mansouri, Feizollah , Sio, Terence T. , Sullman, Mark J. M. , Carson‐Chahhoud, Kristin , Hosseinzadeh, Rezvan , Barary, Mohammad , Ebrahimpour, Soheil , Mohseni Afshar, Zeinab , Babazadeh, Arefeh , Janbakhsh, Alireza , Mansouri, Feizollah , Sio, Terence T , Sullman, Mark J M , Carson-Chahhoud, Kristin , Hosseinzadeh, Rezvan , Barary, Mohammad , Ebrahimpour, Soheil

Mayo Clinic

Reviews in Medical Virology | October 22, 2021 | Volume: 32 | Issue: 3 | Pages: No page available

10.1002/rmv.2309 | PMID 34677889 Get It

SummaryVaccination against severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) is a crucial step in ending the current worldwide pandemic. However, several particularly vulnerable groups in the population were not included in sufficient numbers in coronavirus disease 2019 (Covid‐19) vaccine trials. Therefore, as science advances, the advice for vaccinating these special populations against Covid‐19 will continue to evolve. This focused review provides the latest recommendations and considerations for these special populations (i.e., patients with rheumatologic and autoimmune disorders, cancer, transplant recipients, chronic liver diseases, end‐stage renal disease, neurologic disorders, psychiatric disorders, diabetes mellitus, obesity, cardiovascular diseases, chronic obstructive pulmonary disease, human immunodeficiency virus, current smokers, pregnant and breastfeeding women, the elderly, children, and patients with allergic reactions) using the currently available research evidence.
Abstract MP05: Mid-Life Vitamin D Levels are Not Associated with Cognition and Dementia Risk in Whites and Blacks: the Atherosclerosis Risk in Communities (ARIC) Study
Sharrett, A. Richey , Schneider, Andrea L.C. , Lutsey, Pamela L. , Alonso, Álvaro , Gottesman, Rebecca F. , Carson, Kathryn A. , Post, Wendy S. , Knopman, David S. , Mosley, Thomas H. , Michos, Erin D.

Mayo Clinic

Circulation | July 3, 2021 | Volume: 129 | Issue: suppl_1 | Pages: No page available

10.1161/circ.129.suppl_1.mp05 Get It

Introduction: Recent studies, mainly performed in elderly whites, suggest that vitamin D, measured by 25-hydroxyvitamin D [25(OH)D], is important for cognition. Less is known about the association of 25(OH)D measured in mid-life with cognition and dementia risk in whites and blacks. Hypothesis: We hypothesized that lower concentrations of 25(OH)D would be associated cross-sectionally with lower cognitive test scores and prospectively with greater decline in cognitive test scores and with increased risk of dementia. Methods: We conducted cross-sectional (1993-1995), change (1993-1995 to 2004-2006), and prospective (follow-up through 2010) analyses of 1,652 participants in the ARIC Brain Ancillary Study with measured 25(OH)D (1993-1995). 25(OH)D was analyzed in race-specific tertiles and continuously. Cognition was measured by 3 tests: Delayed Word Recall (DWR), Digit Symbol Substitution (DSS), and Word Fluency (WF). Dementia was defined by hospitalization ICD-9 codes. Adjusted race-stratified linear regression and Cox proportional hazards models were used. Results: Mean age of participants was 62 years, 60% were female, and 48% were black. Mean 25(OH)D was higher in whites than blacks (25.5 versus 17.3 ng/ml, p<0.05). Over a median of 16.6 years, there were 145 incident hospitalized dementia cases. In prospective analyses, lower levels of 25(OH)D trended towards an association with increased dementia risk in whites and in blacks, but these results were not statistically significant (lowest versus highest tertile: whites, HR: 1.32 [95% CI: 0.69, 2.55]; blacks, HR: 1.53 [95% CI: 0.84, 2.79]) (Figure). Conclusion: In contrast to prior studies performed in elderly populations, our study did not find significant associations between lower levels of 25(OH)D in mid-life with lower cognitive test scores at baseline, change in score over time, or increased dementia risk.
Ultrasonic Percutaneous Tenotomy for Recalcitrant Lateral Elbow Tendinopathy: Clinical and Sonographic Results at 90 Months
Ang, Benjamin F.H., Mohan, P. Chandra, Png, Meng Ai , Howe, Tet Sen , Morrey, B.F. , Morrey, Bernard F, Mohan, P. Chandra, Allen, John Carson , Koh, Joyce Suang Bee , Lee, Brian P.

Mayo Clinic

The American Journal of Sports Medicine | May 9, 2021 | Volume: 49 | Issue: 7 | Pages: 1854-1860

10.1177/03635465211010158 | PMID 33956537 Get It

Background: In a study from our institution, ultrasonic percutaneous tenotomy of the brevis and the common extensor tendon for recalcitrant lateral elbow tendinopathy showed excellent safety profiles, high tolerability, efficiency, sustained pain relief, functional improvement, and sonographic evidence of tissue healing in 20 patients at 3 years’ follow-up. Purpose: To explore the long-term clinical and sonographic results of ultrasonic percutaneous tenotomy of the brevis and the common extensor tendon. Study Design: Case series; Level of evidence, 4. Methods: The same cohort of 20 patients was recalled after 7 years, and visual analog scale (VAS) for pain and Disabilities of the Arm, Shoulder and Hand (DASH) scores, need for secondary intervention, and overall satisfaction were assessed. They were also reassessed using ultrasound imaging of the brevis and the common extensor tendon to evaluate tendon hypervascularity, tendon thickness, and the progress or the recurrence of the hypoechoic scar tissue. Results: We successfully scored 19 patients and performed ultrasound on 16 patients with a median follow-up of 90 months (range, 86-102 months). There were no adverse outcomes and satisfaction remained at 100% (6 patients, satisfied; 13 patients, very satisfied). No patient developed a recurrence of symptoms and signs of lateral elbow tendinopathy, and therefore no secondary intervention was required. The improvement from baseline and early term scores was sustained ( P < .001 for all). At 90 months, there was a significant improvement in VAS scores and DASH–Compulsory scores compared with preprocedure scores and all follow-up times until 3 months. There was no difference in VAS scores and DASH–Compulsory scores at 90 months compared with 6 and 36 months. For DASH–Work scores, there was a significant improvement at 90 months compared with preprocedure scores, but there was no difference between DASH–Work scores at 90 months and scores at all other points of follow-up. At 90 months, hypervascularity remained resolved in 79% of patients, while all patients had reduced tendon swelling and sustained resolution or reduction of the hypoechoic lesion. Conclusion: At the long-term follow-up of 90 months, ultrasonic percutaneous tenotomy of the brevis and the common extensor tendon, previously shown to enhance recovery of lateral elbow tendinopathy, demonstrated good durability of pain relief and functional recovery that was previously achieved. This was accompanied by sustained sonographic tissue healing with no significant deterioration.
Biallelic splicing variants in the nucleolar 60S assembly factor RBM28 cause the ribosomopathy ANE syndrome
Bryant, Carson J. , Lorea, Cláudia Fernandes , Almeida, Hiram Larangeira de , Weinert, Letícia Schwerz , Vedolin, Leonardo , Baserga, Susan J. , Lorea, Cláudia F , de Almeida, Hiram Larangeira , Weinert, Letícia , Vairo, Filippo , Baserga, Susan J , Vairo, Filippo Pinto e

Mayo Clinic

Proceedings of the National Academy of Sciences | May 3, 2021 | Volume: 118 | Issue: 19 | Pages: No page available

10.1073/pnas.2017777118 | PMID 33941690 Get It

Significance RBM28 is a human protein essential for proper assembly of the large ribosomal subunit, crucially enabling synthesis of all cellular proteins. Defects in RBM28 cause rare ribosomopathies: alopecia, neurological defects, and endocrinopathy (ANE) syndrome. We investigated an ANE syndrome patient with a clinical presentation consistent with the definition of ANE syndrome but possessing differing genetic variants and molecular pathology. We find one inherited allele is null, clarifying that ANE syndrome is not caused by RBM28 haploinsufficiency, while the other inherited allele retains enough function to enable survival but preclude proper development. Our results define an underlying pathology of ANE syndrome, further delineating an emerging class of assembly factor ribosomopathies and underscoring the importance of nucleolar processes in human health.
Phase 2 study of ibrutinib in classic and variant hairy cell leukemia
Rogers, Kerry A. , Andritsos, Leslie A. , Wei, Lai , McLaughlin, Eric , Ruppert, Amy S. , Anghelina, Mirela , Blachly, James S. , Call, Timothy G. , Chihara, Dai , Dauki, Anees M. , James, Lacey, Kreitman, Robert J. , Lozanski, Gerard , Lucas, David , Ngankeu, Apollinaire, Phelps, Mitch A. , Schiffer, Charles A. , Carson, William E. , Jones, Jeffrey A. , Grever, Michael R. , Call, Timothy, Dauki, Anees , Carson, William E , Wei, Lai , Chihara, Dai , Blachly, James , Phelps, Mitch , Guo, Ling Jun , Ivy, S. Percy , Jones, Daniel R. , Ravandi, Farhad

Mayo Clinic

Blood | March 23, 2021 | Volume: 137 | Issue: 25 | Pages: 3473-3483

10.1182/blood.2020009688 | PMID 33754642 Get It

Abstract Hairy cell leukemia (HCL) is a rare B-cell malignancy, and there is a need for novel treatments for patients who do not benefit from purine analogs. Ibrutinib, an oral agent targeting Bruton tyrosine kinase in the B-cell receptor signaling pathway, is highly effective in several malignancies. Its activity in HCL was unknown, so we conducted a multisite phase 2 study of oral ibrutinib in patients with either relapsed classic or variant hairy cell leukemia. The primary outcome measure was the overall response rate (ORR) at 32 weeks, and we also assessed response at 48 weeks and best response during treatment. Key secondary objectives were characterization of toxicity and determination of progression-free survival (PFS) and overall survival (OS). Thirty-seven patients were enrolled at 2 different doses (24 at 420 mg, 13 at 840 mg). The median duration of follow-up was 3.5 years (range, 0-5.9 years). The ORR at 32 weeks was 24%, which increased to 36% at 48 weeks. The best ORR was 54%. The estimated 36-month PFS was 73% and OS was 85%. The most frequent adverse events were diarrhea (59%), fatigue (54%), myalgia (54%), and nausea (51%). Hematologic adverse events were common: anemia (43%), thrombocytopenia (41%), and neutropenia (35%). Ibrutinib can be safely administered to patients with HCL with objective responses and results in prolonged disease control. Although the initial primary outcome objective of the study was not met, the observation of objective responses in heavily pretreated patients coupled with a favorable PFS suggests that ibrutinib may be beneficial in these patients. This trial was registered at www.clinicaltrials.gov as #NCT01841723.